BAIAP2L2 promotes gastric cancer cell proliferation and metastasis via activation of AKT/mTOR and Wnt3α/β-catenin pathways, while serving as a prognostic marker in non-small cell lung cancer patients with low PD-1 and EGFR expression (22, 23). Here, EGFR is linked to non-small cell lung carcinoma.